LEADER 03604nam 2200457 450 001 9910573096703321 005 20221201214228.0 010 $a1-119-78343-7 010 $a1-119-78342-9 035 $a(MiAaPQ)EBC6983460 035 $a(Au-PeEL)EBL6983460 035 $a(CKB)22249455400041 035 $a(EXLCZ)9922249455400041 100 $a20221201d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCarbon monoxide in drug discovery $ebasics, pharmacology, and therapeutic potential /$fedited by Leo E. Otterbein, Binghe Wang 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons, Inc.,$d[2022] 210 4$dİ2022 215 $a1 online resource (1005 pages) 225 1 $aWiley Series in Drug Discovery and Development Ser. 300 $aIncludes index. 311 08$aPrint version: Wang, Binghe Carbon Monoxide in Drug Discovery Newark : John Wiley & Sons, Incorporated,c2022 9781119783404 327 $aIntro -- Carbon Monoxide in Drug Discovery -- Contents -- List of Contributors -- Preface: Carbon Monoxide: Promises and Challenges in Its Pharmaceutical Development -- Section I General Background and Physiological Actions -- 1 Endogenous CO Production in Sickness and in Health -- 2 Molecular Mechanisms of Actions for CO: An Overview -- 3 Pharmacokinetic Characteristics of Carbon Monoxide -- 4 Carbon Monoxide and Energy Metabolism -- 5 Role of CO in Circadian Clock -- 6 Carbon Monoxide and Mitochondria -- 7 Carbon Monoxide, Oxygen, and Pseudohypoxia -- 8 Nitric Oxide in Human Physiology: Production, Regulation, and Interaction with Carbon Monoxide Signaling -- 9 When Carbon Monoxide Meets Hydrogen Sulfide -- 10 Biliverdin and Bilirubin as Parallel Products of CO Formation: Not Just Bystanders -- Section II Delivery Forms -- 11 Delivery Systems and Noncarrier Formulations -- 12 Metal-Based Carbon Monoxide-Releasing Molecules (CO-RMs) as Pharmacologically Active Therapeutics -- 13 Organic CO Donors that Rely on Photolysis for CO Release -- 14 Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions -- 15 Targeted Delivery of Carbon Monoxide -- 16 Anesthesia-Related Carbon Monoxide Exposure -- 17 Natural Products that Generate Carbon Monoxide: Chemistry and Nutritional Implications -- Section III Carbon Monoxide Sensing and Scavenging -- 18 Fluorescent Probes for Intracellular Carbon Monoxide Detection -- Section IV Therapeutic Applications -- 19 CO in Solid Organ Transplantation -- 20 Carbon Monoxide in Lung Injury and Disease -- 21 Carbon Monoxide in Acute Brain Injury and Brain Protection -- 22 CO as a Protective Mediator of Liver Injury: The Role of PERK in HO-1/CO-Mediated Maintenance of Cellular Homeostasis in the Liver -- 23 CO and Cancer -- 24 CO and Diabetes -- 25 Carbon Monoxide and Acute Kidney Injury. 327 $a26 CO as an Antiplatelet Agent: An Energy Metabolism Perspective -- 27 CO in Gastrointestinal Physiology and Protection -- 28 Carbon Monoxide and Sickle Cell Disease -- 29 CO and Pain Management -- 30 Clinical Trials of Low-Dose Carbon Monoxide -- Index -- EULA. 410 0$aWiley Series in Drug Discovery and Development Ser. 606 $aDrugs$xResearch 615 0$aDrugs$xResearch. 676 $a615.1072 702 $aWang$b Binghe$f1962- 702 $aOtterbein$b Leo E. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910573096703321 996 $aCarbon monoxide in drug discovery$92983890 997 $aUNINA